Active Biotech: Notice of Annual General Meeting of Shareholders

(Thomson Reuters ONE) -


The Board of Directors of Active Biotech AB (publ) has issued a notice to the
Annual General Meeting, which is to take place on Thursday, May 26, 2016, at 5
pm at Elite Hotel Ideon, Scheelevägen 27 in Lund, Sweden.

Please see the attached notification, which is being announced within short in
Svenska Dagbladet and Post- och Inrikes Tidningar.


Lund, April 26, 2016

ACTIVE BIOTECH AB (PUBL)
THE BOARD OF DIRECTORS

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory properties, is
in pivotal Phase 3 development for the treatment of relapsing remitting multiple
sclerosis. Also, laquinimod is in Phase 2 development for the treatment of
primary progressive multiple sclerosis and Huntington's disease. Furthermore,
commercial activities are conducted for the ISI, ANYARA and paquinimod projects.
Please visit www.activebiotech.com for more information.


Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 05



Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. This information was provided to the media
for publication at 8:30 am CET on April 26, 2016.


160426 Invitation AGM 2016_ENG:
http://hugin.info/1002/R/2006457/741349.pdf



This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and

originality of the information contained therein.

Source: Active Biotech via GlobeNewswire
[HUG#2006457]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 26.04.2016 - 08:30 Uhr
Sprache: Deutsch
News-ID 466350
Anzahl Zeichen: 2270

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 172 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech: Notice of Annual General Meeting of Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech